Session Information
Date: Sunday, November 8, 2026
Title: (0104-0110) Pediatric Rheumatology - Basic and Translational Science Poster A
Session Type: Poster Session A
Session Time: 10:30AM-12:30PM
Background/Purpose: Methotrexate (MTX) is the recommended first-line treatment for children with non-infectious uveitis (NIU), with treatment failure rates as high as 50%. Because therapeutic response may take 3-6 months, delays can lead to prolonged corticosteroid exposure and irreversible ocular complications. Gene expression predictors of MTX response are lacking, and prior studies in inflammatory arthritis patients have produced conflicting results. We, therefore, sought to explore predictors of response to MTX using whole blood transcriptional profiling.
Methods: For this prospective, multicenter study (OptiMTX), we included patients diagnosed with any type of NIU at < 18 y/o starting MTX and pediatric controls (HC). Blood samples were collected within 4 weeks of starting MTX (baseline) and a follow up visit at 3/6/12 months. They were grouped by MTX response as: responders (MTX-R) and inadequate responders (MTX-IR) based on addition of biologic therapy. We compared: 1) baseline samples of MTX-R v MTX-IR, 2) NIU v HC, and 3) baseline vs time of IR. 3mL of blood was drawn directly into the Tempus Blood RNA Tube, and total RNA was extracted via Tempus™ Spin RNA Isolation Kit (Applied Biosystems). We performed globin and rRNA depletion prior to library construction, and equimolar pooled libraries were sequenced on Illumina NovaSeq X with ~60M reads per sample. Samples were aligned using the NF-Core RNAseq pipeline (v3.18.0) for bulk samples, built inside a NextFlow scaffold (v24.10.1). Filtered reads were aligned to the hg38 reference genome with STAR (2.6.1d) and counted with Salmon (1.10.3). A log2 fold change cutoff ≥0.4 and pvalue ≤0.05 were used to determine statistical significance.
Results: There were 20 patients (14 MTX-IR, 6 MTX-R) and 5 HC. Examining baseline gene expression signatures, there was substantial patient-level heterogeneity. Comparing all patients to healthy controls, we observed an upregulated gene expression signature enriched in pathways including heme metabolism (p=0.019), chemokine receptors (p=0.047), and IL-10 signaling (p=0.044). When examining baseline signatures between MTX-R and MTX-IR, the most enriched gene pathway was interferon alpha response (p=0.14) including IFI27 and TRIM14. Other positively enriched gene pathways included regulation of extrinsic apoptotic signaling and positive regulation of erythrocyte differentiation. Finally, we examined changes in transcriptional profiles at follow-up compared to baseline, regardless of treatment response, and observed a strong downregulated signature including CXCL10.
Conclusion: Whole blood transcriptional profiles from children with NIU demonstrate substantial variability. This pilot study nominates genes and pathways associated with MTX response including interferon alpha pathway. Further work will validate these findings and integrate gene expression signatures with other clinical and imaging features of NIU to support a predictive model of MTX response.
To cite this abstract in AMA style:
Schulert G, Do T, Kuenzi Davis A, Straus E, Jagger A, Chang M, Altaye M, Utz V, Brunner H, Zeft A, Srivastava S, Stahl E, Cooper A, Nihalani-Gangwani B, Lo M, Quinlan-Waters M, Duell A, Angeles-Han S. Gene expression signatures as predictors of response to methotrexate in pediatric non-infectious uveitis (NIU). [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/gene-expression-signatures-as-predictors-of-response-to-methotrexate-in-pediatric-non-infectious-uveitis-niu/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expression-signatures-as-predictors-of-response-to-methotrexate-in-pediatric-non-infectious-uveitis-niu/
